The company posted a loss of 39 cents when the street was looking for a profit of 95…
Operating income for the full fiscal year was $119.2 million, compared to a loss of $97.7 million in…
Kohl's had rejected Acacia Research's $64 per share bid earlier this year.
The company is in Phase 3 trials with atrasentan for IgA nephropathy (IgAN).
Revenue was flat year-over-year, and the company forecast a surprise decline in the current quarter.
No reason was given for the departure.
Target stock lost 25% of its value on Wednesday.
The VIX is akin to an insurance policy on the markets.
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
